GSK plc (BCBA:GSK)

Market Cap	138.43T
Revenue (ttm)	59.26T
Net Income (ttm)	10.12T
Shares Out	n/a
EPS (ttm)	2,447.74
PE Ratio	13.68
Forward PE	9.93
Dividend	476.22 (2.62%)
Ex-Dividend Date	Nov 14, 2025

Volume	58
Average Volume	284
Open	18,360
Previous Close	18,430
Day's Range	18,150 - 18,360
52-Week Range	9,110 - 18,880
Beta	n/a
RSI	54.69
Earnings Date	Feb 4, 2026

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a...

• Industry: Pharmaceutical Preparations
• Founded: 1715
• Employees: 68,629
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: GSK

Financial Performance

In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.

Financial numbers in GBP